Demographics and baseline disease characteristics. Data are mean (SD) (range) unless otherwise indicated.
| Characteristic | Safety Population, n = 176 |
|---|---|
| Age, yrs | 53.6 (11.7) (18–80) |
| Female, % | 87.5 |
| White, % | 79.0 |
| No. prior DMARD* | 4.0 (1.6) (1–10) |
| No. prior TNF inhibitors | 1.5 (0.6) (0–3) |
| Disease duration, yrs | 10.6 (9.0) (0–41.7) |
| RF-positive, % | 61.4 |
| ACPA-positive, % | 62.5 |
| CRP, mg/dl | 1.26 (2.68) (0.02–28.40) |
| ESR, mm/h | 32.7 (24.3) (1.0–30.0) |
| DAS28-ESR† | 6.21 (1.05) (2.5–8.8) |
| SJC (of 66 joints) | 19.0 (11.0) (5–59) |
| TJC (of 68 joints) | 29.5 (15.7) (6–68) |
| HAQ-DI | 1.47 (0.64) (0.0–3.0) |
| Oral steroid use, % | 39.2 |
| One steroid use, mg/day | 6.5 (2.7) (1.0–10.0) |
↵* Biologic and nonbiologic DMARD, including methotrexate. Excluding methotrexate, patients had received a mean of 3.0 prior biologic and nonbiologic DMARD.
↵† While taking baseline biologic/nonbiologic DMARD. ACPA: anticitrullinated protein antibody; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; DMARD: disease-modifying antirheumatic drug; ESR: erythrocyte sedimentation rate; HAQ-DI: Health Assessment Questionnaire-Disability Index; RF: rheumatoid factor; SJC: swollen joint count; TJC: tender joint count; TNF: tumor necrosis factor.